STOCK TITAN

VolitionRx Limited - $VNRX STOCK NEWS

Welcome to our dedicated page for VolitionRx news (Ticker: $VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRx stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VolitionRx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VolitionRx's position in the market.

Rhea-AI Summary
VolitionRx hosts KOL roundtable on sepsis, discussing challenges and potential treatments, including Volition's Nu.Q® NETs test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.73%
Tags
none
-
Rhea-AI Summary
VolitionRx announces financial results and business update for Q2 2023, with revenue exceeding full year 2022 revenue. Breakthrough Device Designation Request submitted to FDA for Nu.Q® technology in relation to sepsis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
-
Rhea-AI Summary
VolitionRx Limited announces the pricing of an underwritten public offering of its common stock, expecting to raise $16.5 million. The company also grants the underwriters an option to purchase additional shares. The offering is expected to close on June 5, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
-
Rhea-AI Summary
VolitionRx announces financial results and business update for Q1 2023, reporting a 381% increase in sales for the Nu.Q Vet Cancer Test. They also provide updates on the progress of the Nu.Q NETs test and upcoming launches in additional countries. Volition is hosting a Capital Markets Day to provide strategic updates on both tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
VolitionRx Limited

NYSE:VNRX

VNRX Rankings

VNRX Stock Data

63.77M
62.70M
23.92%
7.97%
0.6%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
HENDERSON

About VNRX

volitionrx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats. volitionrx’s development activities are currently centered in belgium with a focus on bringing its revolutionary diagnostic products to market first in europe, then the u.s. and worldwide. you can find more information about volitionrx at our website at www.volitionrx.com, on twitter at www.twitter.com/volitionrx, linkedin at http://www.linkedin.com/company/volitionrx or facebook at www.facebook.com/volitionrx.